Wall Street Journal regarding general trends with Abbot.
https://www.wsj.com/articles/rapid-covid-tests-cant-keep-abbott-healthy-forever-11666200129 "One challenge for investors is that no one knows how long people will keep taking those antigen tests. The company itself is being very cautious, forecasting a meager $500 million in sales in the fourth quarter, which would be a huge sequential decline from the third quarter, even though we are entering winter months. That seems overly conservative, and executives admitted as much during a call on Wednesday, telling analysts that “Covid test sales are stickier than most have assumed.”
Covid 19 has been good and bad for Abbot, for example, and these facts may also be applied to AT1 in many ways.
For Rick Wise, an analyst at Stifel, much of the decline may be because investors came “into the quarter feeling this will be a great one, but there wasn’t any ‘oh wow’ factor.” But the company, he says, “got it done in a complicated environment.” I feel this applies to AT1.
Tha pandemic is hurting Abbott's traditional business, and this is similar to how Atomo's HIV business was hurt in 20-21.
